SBIR-STTR Award

The Long Term Objective of This Line of Investigation Is to Develop a New Class of Antivirals Which Are Effective Against a Wide Variety of Infections, Are Safe for Human Use, Economical to Produce and Enhance Resistance to Or Recovery from Viral
Award last edited on: 3/26/2021

Sponsored Program
SBIR
Awarding Agency
DOD : Navy
Total Award Amount
$49,700
Award Phase
1
Solicitation Topic Code
N85-006
Principal Investigator
Michael C Trachtenberg

Company Information

NeuroGenesis Inc (AKA: Matrix Technologies Inc)

1241 Butler Road
League City, TX 77573
   (281) 557-7877
   info@neurogenesis.com
   www.neurogenesis.com
Location: Single
Congr. District: 14
County: Galveston

Phase I

Contract Number: 07921
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1985
Phase I Amount
$49,700
The long term objective of this line of investigation is to develop a new class of antivirals which are effective against a wide variety of infections, are safe for human use, economical to produce and enhance resistance to or recovery from viral infectious agents. The agents may have application in conjunction with known immunopotentiators recent experimental data indicate that a variety of common organic and inorganic compounds possess decided antiviral properties and constitute a potentially important class of antiviral agents. The data indicate that these agents are effective both in vitro and in vivo. During phase i, matrix will conduct tissue culture and preliminary intact animal studies of the prophylactic and therapeutic efficacy of four of the most promising compounds against respiratory, influenza and encephalitis viruses.

Keywords:

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----